Healthcare & Biotech Hedge Funds Reach New Heights as Assets Peak at $172 billion
|February 15th, 2016||
|Despite the overall challenging environment, the Top Healthcare, Pharma and Biotech Focused Hedge Fund list managed to realize asset gains over the past quarter. The top funds now manage $172.2 billion in assets, an all-time high for the list. Leading the list’s top gainers are Sachem Head Capital Management, Visium Asset Management and Third Point Management Company. |
Scott Ferguson’s Sachem Head Capital reported equity assets of $2.2 billion, allocating 49% of its assets to healthcare and biotech stocks. Sachem Capital is also ranked #10 on the Top Emerging Hedge Fund Managers list and #19 on the Top Activist Hedge Fund list. The fund’s top sector positions include Allergan plc (AGN) and Zoetis Inc (ZTS).
Jacob Gottlieb’s Visium Asset Management is ranked #8 on the Top Healthcare, Pharma and Biotech List, with nearly $6.9 billion in assets under management. Visium’s top sector positions include Endo Health Solutions (ENDP), Laboratory Corp of America (LH), Perrigo Co (PRGO) and Allergan plc (AGN).
Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms’ overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker’s Hedge Fund Portal.
For Detailed Investor Profiles on these Investors, click below: